Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes.

[1]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[2]  E. Messing,et al.  Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. , 2015, Urologic oncology.

[3]  L. Kiemeney,et al.  The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. , 2015, Urologic oncology.

[4]  R. Sosnowski,et al.  The role of the urologist in smoking cessation: why is it important? , 2015, Urologic oncology.

[5]  T. Todenhöfer,et al.  Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence. , 2014, Urologic oncology.

[6]  S. Shariat,et al.  Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer , 2014, Current opinion in urology.

[7]  William Wheeler,et al.  Genome-wide interaction study of smoking and bladder cancer risk. , 2014, Carcinogenesis.

[8]  S. Shariat,et al.  Re: Global effects of smoking, of quitting, and of taxing tobacco. , 2014, European urology.

[9]  Y. Lotan,et al.  Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. , 2014, Urologic oncology.

[10]  N. Petersen,et al.  Educational Opportunities in Bladder Cancer: Increasing Cystoscopic Adherence and the Availability of Smoking-Cessation Programs , 2014, Journal of Cancer Education.

[11]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[12]  Jie Jin,et al.  Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG , 2014, Pakistan journal of medical sciences.

[13]  C. Marsit,et al.  Body mass and smoking are modifiable risk factors for recurrent bladder cancer , 2014, Cancer.

[14]  L. Thuler,et al.  The magnitude of the association between smoking and the risk of developing cancer in Brazil: a multicenter study , 2014, BMJ Open.

[15]  C. la Vecchia,et al.  Smoking, occupation, history of selected diseases and bladder cancer risk in Manisa, Turkey , 2014, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[16]  I. Ahmed,et al.  Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG , 2014, Pakistan journal of medical sciences.

[17]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[18]  E. White,et al.  Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study. , 2014, Urologic oncology.

[19]  R. Peto,et al.  Global effects of smoking, of quitting, and of taxing tobacco. , 2014, The New England journal of medicine.

[20]  B. Bochner,et al.  The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer , 2014, World Journal of Urology.

[21]  C. Ferreccio,et al.  Arsenic, Tobacco Smoke, and Occupation: Associations of Multiple Agents with Lung and Bladder Cancer , 2013, Epidemiology.

[22]  Ronald Sroka,et al.  Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL). , 2013, Urologic oncology.

[23]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[24]  M. Babjuk,et al.  Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. , 2013, European urology.

[25]  M. Babjuk,et al.  Gender‐specific effect of smoking on upper tract urothelial carcinoma outcomes , 2013, BJU international.

[26]  Y. Hsueh,et al.  Environmental tobacco smoke and arsenic methylation capacity are associated with urothelial carcinoma. , 2013, Journal of the Formosan Medical Association = Taiwan yi zhi.

[27]  Y. Lotan,et al.  Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder , 2013, British Journal of Cancer.

[28]  M. Babjuk,et al.  Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. , 2013, European urology.

[29]  Nilanjan Chatterjee,et al.  Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. , 2013, Cancer research.

[30]  David A. Green,et al.  Predictors of cancer‐specific mortality after disease recurrence following radical cystectomy , 2013, BJU international.

[31]  G. Morgia,et al.  Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. , 2013, Urology.

[32]  M. Babjuk,et al.  Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. , 2013, European urology.

[33]  M. Babjuk,et al.  Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. , 2012, The Journal of urology.

[34]  M. Babjuk,et al.  Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer. , 2012, European urology.

[35]  Choung-Soo Kim,et al.  Smoking and survival after radical cystectomy for bladder cancer. , 2012, Urology.

[36]  F. Ajili,et al.  Tumor Multiplicity Is an Independent Prognostic Factor of Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin Immunotherapy , 2012, Ultrastructural pathology.

[37]  S. Land.  Methodologic barriers to addressing critical questions about tobacco and cancer prognosis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  F. Chun,et al.  [Advanced bladder cancer in elderly patients. Prognostic outcomes and therapeutic strategies]. , 2012, Der Urologe. Ausg. A.

[39]  J. Gore,et al.  Impact of a bladder cancer diagnosis on smoking behavior. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  F. Brimo,et al.  Prognostic factors and outcome in patients with T1 high‐grade bladder cancer: can we identify patients for early cystectomy? , 2012, BJU international.

[41]  David A. Green,et al.  Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes , 2012, Current Urology Reports.

[42]  M. Pike,et al.  Cigarette smoking and subtypes of bladder cancer , 2012, International journal of cancer.

[43]  T. H. van der Kwast,et al.  Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer , 2012, BJU international.

[44]  S. Shariat,et al.  Can we apply nomograms derived in the United States to European patients? Yes, we can! , 2012, European urology.

[45]  T. Guzzo,et al.  Smoking knowledge assessment and cessation trends in patients with bladder cancer presenting to a tertiary referral center. , 2012, Urology.

[46]  T. Guzzo,et al.  A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Shariat,et al.  Das fortgeschrittene Urothelkarzinom der Harnblase beim älteren Patienten , 2012, Der Urologe.

[48]  D. Saleh,et al.  Urinary Bladder Cancer Risk Factors in Egypt: A Multicenter Case–Control Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[49]  J. Cheville,et al.  Risk factors and outcomes of urethral recurrence following radical cystectomy. , 2011, European urology.

[50]  Kwangsung Park,et al.  Impact of diabetes mellitus on recurrence and progression in patients with non‐muscle invasive bladder carcinoma: A retrospective cohort study , 2011, International journal of urology : official journal of the Japanese Urological Association.

[51]  J. Witjes,et al.  Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. , 2011, European urology.

[52]  D. Silverman,et al.  Association between smoking and risk of bladder cancer among men and women. , 2011, JAMA.

[53]  S. Shariat,et al.  Impact of smoking on outcomes after intravesical bacillus Calmette–Guérin therapy for urothelial carcinoma not invading muscle of the bladder , 2011, BJU international.

[54]  L. Lacombe,et al.  Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience , 2011, BJU international.

[55]  D. Lamm.  IMPACT OF SMOKING ON OUTCOMES AFTER INTRAVESICAL BACILLUS CALMETTE–GUÉRIN THERAPY FOR UROTHELIAL CARCINOMA NOT INVADING MUSCLE OF THE BLADDER , 2011, BJU international.

[56]  S. Shariat,et al.  Impact of gender on bladder cancer incidence, staging, and prognosis , 2011, World Journal of Urology.

[57]  N. Malats,et al.  Urinary pH, cigarette smoking and bladder cancer risk. , 2011, Carcinogenesis.

[58]  S. Dube,et al.  Vital signs: Current cigarette smoking among adults aged >=18 years --- United States, 2009 , 2010 .

[59]  R. D. Mittal,et al.  Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India , 2010, Medical oncology.

[60]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[61]  D. Schilling,et al.  Economic aspects of bladder cancer: what are the benefits and costs? , 2009, World Journal of Urology.

[62]  E. Messing,et al.  Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette‐Guérin , 2009, BJU international.

[63]  J. Montie,et al.  The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. , 2008, The Journal of urology.

[64]  C. Shun,et al.  Stopping smoking might reduce tumour recurrence in nonmuscle‐invasive bladder cancer , 2007, BJU international.

[65]  R. Morice,et al.  Original Research: Lung CancerSmoking Cessation After Diagnosis of Lung Cancer Is Associated With a Beneficial Effect on Performance Status , 2006 .

[66]  R. Morice,et al.  Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. , 2006, Chest.

[67]  Yair Lotan,et al.  Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy , 2006, Clinical Cancer Research.

[68]  K. Straif,et al.  Reversal of risk upon quitting smoking , 2006, The Lancet.

[69]  Liang Cheng,et al.  Bladder cancer: epidemiology, staging and grading, and diagnosis. , 2005, Urology.

[70]  L. Sarna,et al.  Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious , 2005, Cancer Epidemiology Biomarkers & Prevention.

[71]  J. Mackenbach,et al.  Trends in smoking behaviour between 1985 and 2000 in nine European countries by education , 2005, Journal of Epidemiology and Community Health.

[72]  M. Sopori,et al.  Effects of cigarette smoke on the immune system , 2002, Nature Reviews Immunology.

[73]  E Dorant,et al.  The impact of characteristics of cigarette smoking on urinary tract cancer risk , 2000, Cancer.

[74]  P. Russo,et al.  Influence of smoking status on the disease‐related outcomes of patients with tobacco‐associated superficial transitional cell carcinoma of the bladder , 1999, Cancer.

[75]  D. Bostwick,et al.  Predicting cancer progression in patients with stage T1 bladder carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  C. Cordon-Cardo,et al.  Cigarette smoking and chromosome 9 alterations in bladder cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[77]  B. Têtu,et al.  Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  R. Dodge,et al.  Clinical variables which serve as predictors of cancer‐specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate , 1994, Cancer.

[79]  C. Cordon-Cardo,et al.  Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.